What You Should Know
- Medidata, a Dassault Systèmes brand, has launched Medidata Plus, an embedded clinical artificial intelligence layer designed to unlock scalable AI capabilities across the entire Medidata Platform.
- While 92% of life sciences decision-makers plan to increase AI spend, only 29% report AI meets their expectations. Medidata Plus eliminates disparate point solutions, providing a predictable, standardized data layer across the trial lifecycle.
- Automates Electronic Data Capture (EDC) and Electronic Clinical Outcome Assessment (eCOA) design while generating synthetic patient data for testing—compressing study build timelines from weeks to mere hours.
- Ingests and standardizes clinical and real-world data without coding, featuring agentic natural-language AI to query audit histories and embedded predictive analytics to flag enrollment and safety risks early.
How Medidata Plus Unifies Clinical R&D Across Global Portfolios
The clinical research, biopharmaceutical R&D, and Contract Research Organization (CRO) sectors are facing an efficiency bottleneck. While 92% of life sciences decision-makers plan to increase AI investments, only 29% state that their current AI deployments meet or exceed expectations.
This disparity stems from vendor and tool fragmentation. Over the past several years, sponsors and CROs adopted an array of disconnected, single-use AI tools—stitching together specialized software for study design, site selection, patient recruiting, and data management.
This patchwork approach created unpredictable software expenses, fragmented data silos, and complex integration requirements that ultimately slowed down clinical trial timelines.
To eliminate point-solution complexity and standardize artificial intelligence across the entire clinical development lifecycle, Medidata has announced the launch of Medidata Plus, a unified clinical AI layer built directly into the Medidata Platform.
By replacing fragmented point solutions with an end-to-end AI foundation, Medidata Plus provides global biopharma leaders and CROs with a drop-in AI strategy that delivers predictable costs, streamlined data governance, and accelerated trial execution.
No-Code Transformation and Agentic Audit Exploration
Medidata Plus introduces a clinically fluent intelligence layer across every operational phase of global trial execution:
- Accelerated Study Builds: Reduces initial setup timelines from weeks to hours by automating EDC and eCOA workflow generation and constructing synthetic patient datasets for rapid User Acceptance Testing (UAT).
- No-Code Data Transformation: Standardizes and harmonizes data streams across disparate clinical trial management systems (CTMS), wearable sensors, and real-world data (RWD) sources without custom programming.
- Proactive Risk Triage: Leverages real-time predictive analytics to detect enrollment downtrends and early safety signals, mitigating mid-trial pauses and streamlining regulatory inspection readiness.
- Agentic AI Audit Mining: Enables study teams to interrogate end-to-end audit logs using natural-language queries, converting complex compliance data into immediate, actionable regulatory intelligence.
“Stitching together point solutions isn’t a strategy — it’s a liability. Drug development’s next leap will come when AI is consistent, connected, and portfolio-wide,” stated Dr. Nimita Limaye, Research VP, Life Sciences R&D Strategy and Technology at IDC. “Medidata Plus delivers this with a cohesive AI layer across the entire lifecycle.”
Discussion about this post